Northwest Biotherapeutics, Inc. Common stock
NWBO
NWBO was delisted on the 16th of December, 2016.
8 hedge funds and large institutions have $414K invested in Northwest Biotherapeutics, Inc. Common stock in 2026 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 0 closing their positions.
397% more capital invested
Capital invested by funds: $83.3K → $414K (+$330K)
0% more funds holding
Funds holding: 8 → 8 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KFA
Kelleher Financial Advisors
New York
|
+$112K |
Top Sellers
NWBO Hedge Fund Activity: Q2 2026 in Review
8 of the 8,330 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q2 2026, worth a combined $414K — up 397% from $83.3K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new NWBO positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Kelleher Financial Advisors, adding an estimated $112K.
- 8 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $414K of Northwest Biotherapeutics, Inc. Common stock stock for Q2 2026, up 397% quarter-over-quarter.
- 1 fund opened new Northwest Biotherapeutics, Inc. Common stock positions in Q2 2026 and 0 closed out, a net change of +1 holder.
- The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q2 2026 was Kelleher Financial Advisors, an estimated $112K added.
Based on aggregated 13F filings for Q2 2026.